Skip Navigation LinksHome > February 2014 - Volume 22 - Issue 2 > Claudin-3 and Claudin-4: Distinct Prognostic Significance i...
Applied Immunohistochemistry & Molecular Morphology:
doi: 10.1097/PAI.0b013e31828d9d62
Research Articles

Claudin-3 and Claudin-4: Distinct Prognostic Significance in Triple-Negative and Luminal Breast Cancer

Kolokytha, Panagiota MD*; Yiannou, Petros MD; Keramopoulos, Dimitris MD; Kolokythas, Argyrios MS-V§; Nonni, Afroditi MD, PhD*; Patsouris, Efstratios MD, PhD*; Pavlakis, Kitty MD, PhD*

Collapse Box


Introduction: To investigate the immunohistochemical expression of claudin-1, claudin-3, and claudin-4 in triple-negative breast carcinomas and compare it with several clinicopathologic parameters as well as their expression in luminal cancers.

Materials and Methods: A total of 128 cases of breast carcinoma were included in the study. For all these cases, immunohistochemistry for estrogen and progesterone receptors, Ki-67, and Her2 had already been performed, whereas Her2 2+ cases had been further characterized as positive or negative for Her2 amplification with the chromogenic in situ hybridization technique. Seventy-six tumors were triple negative. The remaining 52 were luminal cancers. All tumors were evaluated for the expression of claudin-1, claudin-3, and claudin-4.

Results: In the triple-negative group, the positive expression of claudin-3 and claudin-4 was related to unfavorable and favorable prognostic factors, respectively. Claudin-1 was not related to any parameter under evaluation. In the luminal cancer group, claudin-4 positivity was related to a shorter disease-free survival, whereas the inverse was observed for claudin-3. Moreover, all 3 claudins increased with increase of the grade and Ki-67 value in the luminal cancers.

Conclusion: A distinct prognostic significance in the expression of claudin-3 and mostly of claudin-4 between triple-negative and luminal breast carcinomas was identified. Specifically, in triple-negative carcinomas, claudin-4 positivity could probably be considered as a biomarker of favorable prognosis, whereas in luminal cancers with claudin-4-positive expression, the administration of targeted therapy should eventually be part of the patients’ management in the near future.

© 2014 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.